Loss of muscle mass and strength with aging, termed sarcopenia is accelerated in several
comorbidities including chronic heart failure (CHF) and chronic obstructive pulmonary …

Sarcopenia is a gradual loss of skeletal muscle mass and function with aging. Given that
sarcopenia has been recognized as a disease entity, effective molecular biomarkers for …

Biomarkers are emerging as a potential tool for screening or diagnosing sarcopenia. We
aimed to summarize the current evidence on the diagnostic test accuracy of biomarkers for …

The term sarcopenia describes the age-related loss of skeletal muscle mass and function.
While this process, in principal, occurs in every adult person and already starts around the …

Aim To develop a simple screening test to identify older adults at high risk for sarcopenia.
Methods We studied 1971 functionally independent, community‐dwelling adults aged 65 …

Appraisal of muscle mass is important when considering the serious consequences of
sarcopenia in an aging society. However, the associations between sarcopenia and its …

Background The prevalence of sarcopenia is high in older people with type 2 diabetes
mellitus (T2DM) and is now considered a critical problem in the healthcare sector. However …

Introduction It is unclear what combinations of physical capability markers used to define
sarcopenia have the strongest associations with health outcomes. Aim To compare the …

Low muscle mass and function exert a substantial negative impact on quality of life, health
and ultimately survival, but their definition, identification and combination to define …

Simple Summary As we grow older, our muscles become smaller and weaker, a condition
called sarcopenia. Several lung diseases can further worsen sarcopenia. Among them …